FRAXA Research Foundation – Finding a Cure for Fragile X Syndrome

Mission and History

In 1993, three new parents learned that their first-born sons had fragile X syndrome.

There was no fragile X website or Facebook group then, and just a handful of scientists were studying fragile X. There was no hope. The US government was spending only $30,000 per year to find a cure!

They founded FRAXA Research Foundation in 1994 — a nonprofit, tax-exempt organization based in Newburyport, Mass. Committed to finding a cure for fragile X, FRAXA has funded more than $26 million in biomedical research, yielding discoveries that are changing the lives of families coping with fragile X.

FRAXA is one of the most efficient and effective charities in the world, with management and general expenses under 4 percent and research expenditures at 86 percent. Three Nobel Laureates sit on our volunteer Scientific Advisory Board.

FRAXA brochure to download and print

FRAXA Tackles Bottlenecks, Accelerates Progress toward a Cure

Along with funding research, FRAXA runs scientific meetings, advises pharmaceutical companies large and small, and provides education on college campuses, community settings, and international conferences. Families can reach out to FRAXA for resources, guidance, referrals, and an international community of support.

Fragile X research is drastically underfunded, considering its high prevalence, prospects for a cure, and the promise that this research holds for advancing understanding of other disorders like autism, Alzheimer’s disease, and X-linked developmental disabilities.

From our Scientific Advisors

Learn about our research.  How  close are we to finding treatments?

Studies of Fragile X have been galvanized by those most directly affected … experience shows that dedicated, resourceful, and, above all, motivated organizations like FRAXA sometimes do hold the key to cracking these diseases.

James Watson, PhD, Nobel Laureate
Michael_Snape

Now there is an industry-wide pipeline of programs in development across many companies. It is a simple truth that without FRAXA, this would not be the case. The initiatives FRAXA has in place have been, and continue to be, crucial to this critical mass of effort to find new options for people with lives touched by fragile X.

Michael Snape, PhD Amo Pharmaceuticals
mark bear

There is no greater thrill than the realization that one’s basic research might, in the foreseeable future, provide new therapies — and possibly a cure — for Fragile X.

Mark Bear, PhD, MIT fraxa.org/mark-bear

Key Media Coverage

  • New York Times
  • National Public Radio
  • Boston Globe

Playing a Part in Finding a Cure — by Kevin Paul Dupont — May 2015

You Can Help

Since FRAXA was launched, the Fragile X field has grown tremendously. You can help us accomplish much more!

“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”
– Margaret Mead

  • FRAXA AUDITED FINANCIAL STATEMENTS
  • IRS FORM 990
  • IRS Letter of Determination

Dave Bjork, Director of Development dbjork@fraxa.org
Marna Badavas, Member Services mbadavas@fraxa.org
Katie Clapp, Executive Director kclapp@fraxa.org
Michael Tranfaglia, Medical Director mtranfaglia@fraxa.org